Deepak M. Sahasrabudhe

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma

Alyssa K. Steimle, Amir Masoud Forati, Alice Yao Zhou, Trevor McCracken et autres

Background/Objectives: ctDNA is evolving as an important biomarker for prognostic assessment in advanced melanoma. However, the utility of ctDNA monitoring during concurrent ICI with RT remains incompletely explored. Methods: In this multicenter retrospective study, patients with unresectable stage III/IV melanoma treated with …

us (code pays fourni par la source)

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma

Alyssa K. Steimle, Amir M. Forati, Alice Y. Zhou, Trevor McCracken et autres

ctDNA is evolving as an important biomarker for ICI treatment response assessment in advanced melanoma. However, the utility of ctDNA monitoring during concurrent ICI with RT remains incompletely explored. In this multicenter, retrospective study, patients with unresectable stage III/IV melanoma treated with …

Erratum: Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma

Vincent T. Ma, Alice Y. Zhou, Amir Forati, Fauzia Hollnagel et autres

Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma.

Alyssa K. Steimle, Amir W. Forati, Alice Yao Zhou, Trevor McCracken et autres

9533 Background: ctDNA is becoming a useful biomarker for ICI treatment response assessment in advanced melanoma. RT is capable of producing an abscopal effect, potentially enhancing ICI efficacy. The utility of ctDNA monitoring with concurrent ICI and RT remains incompletely explored. Here, …

us (code pays fourni par la source)

Optimal timing of circulating tumor DNA (ctDNA) dynamics to prognosticate immune checkpoint inhibitors (ICI) efficacy in patients with advanced stage melanoma.

Vincent T. Ma, Amir W. Forati, Alice Yao Zhou, Trevor McCracken et autres

9534 Background: ctDNA predicts relapse in resected tumors, but its role in advanced disease is less defined. We previously reported that early ctDNA changes at 3-4 weeks after ICI initiation can inform treatment response and survival. In this study, we attempt to …

us (code pays fourni par la source)

Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma

Vincent T. Ma, Alice Yao Zhou, Amir Forati, Fauzia Hollnagel et autres

PURPOSE The role of circulating tumor DNA (ctDNA) monitoring in predicting treatment response and survival outcomes in early-stage and metastatic solid tumors has shown promising results. The value of early ctDNA dynamics in solid tumors treated with immune checkpoint inhibitors (ICIs) merits …

us (code pays fourni par la source)

The Microbiome and Genitourinary Cancers: A New Frontier

Timothy B. Winslow, Vedha Sai Vaddaraju, Brendan John Guercio, Deepak M. Sahasrabudhe

Introduction of immune checkpoint inhibitors and targeted agents has markedly improved outcomes and extended survival in urothelial and renal cell carcinoma. However, the substantial subset of cases are treatment-resistant. Emerging strategies aim to enhance the effectiveness of immunotherapy. One area of growing …

us (code pays fourni par la source)

SIOG2024-1-P-016 Enzalutamide (Enz) with 5- alpha reductase inhibitors (5-ARI) for older patients (pts) with castration sensitive systemic prostate cancer (CSPC): effects on fatigue and physical wellbeing

S. Kadambi, E. Culakova, Deepak Kilari, Chunkit Fung et autres

In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia

Deepak M. Sahasrabudhe, Jane L. Liesveld, Mohammad Minhajuddin, Niloy A. Singh et autres

Acute myeloid leukemia (AML) is fatal in the majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that immunization of rabbits with normal peripheral WBCs that had been incubated with …

us, in (code pays fourni par la source)

A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).

Deepak Kilari, Sindhuja G Kadambi, Andrea M Baran, Jason Zittel et autres

5089 Background: Older men with prostate cancer who have aging-related conditions are at high risk for adverse events (AEs) from ADT. 5-ARI inhibit the conversion of testosterone to dihydrotesterone and could be synergistic with Enz. In this phase II study, we evaluated …

us (code pays fourni par la source)

Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer

Janice Zhao, Brendan John Guercio, Deepak M. Sahasrabudhe

Prostate cancer is the second most common cancer among men. Despite advances in diagnosis and management, prostate cancer led to more than 300,000 deaths globally in 2020. Chemotherapy is a cornerstone of therapy for advanced prostate cancer and can prolong survival of …

us (code pays fourni par la source)

Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1

Negar Khazan, Emily R. Quarato, Niloy A. Singh, Cameron W. A. Snyder et autres

Small-molecule inhibitors of PD-L1 are postulated to control immune evasion in tumors similar to antibodies that target the PD-L1/PD-1 immune checkpoint axis. However, the identity of targetable PD-L1 inducers is required to develop small-molecule PD-L1 inhibitors. In this study, using chromatin immunoprecipitation …

us, in, fr (code pays fourni par la source)